In 132 healthy Belgian adults, a 10 μg BNT162b2 booster failed non-inferiority to 30 μg for anti-RBD IgG at day 28; titres were similar by month 6. Reactogenicity was lower (41% vs 78%); breakthrough infections were similar (69% vs 62%).
RCTn = 132
Depickère et al. Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial